• Blog
  • Glucagon Market Report

    Glucagon Market Report

    Glucagon Market Report
    Report code - SRHL220 Delivery - 2 Weeks
    Get Free Sample |
    Play Audio
    Listen
    Global Glucagon Market, Dynamics, Market Analysis
    See more...

    Market Insights

    The Global Glucagon Market is expected to grow from USD 486.6 million in 2020 to USD 689.2 million by 2026 at a CAGR of over 6.1% during the forecast period.

    Figure: Global Glucagon Market Size, 2020-2026 (USD Million)

    Glucagon-Market-Forecast

    Wish to get a sample report? Click here.

    Glucagon is defined as a hormone that is produced by the alpha cells in the pancreas and then is released into the bloodstream. It is used to control the blood sugar levels in the human body. It promotes the production of glucose from amino acid molecules. It works along with insulin to control the blood sugar levels and keep them within set levels.

    Key Players

    Key players operating in the global Glucagon Market are-

    • Fresenius SE & Co. KGaA (Germany),
    • Eli Lilly & Co. (The U.S),
    • Novo Nordisk A/S (Denmark),
    • Xeris Pharmaceuticals, Inc. (The U.S),
    • Svar Life Science AB (Sweden),
    • Taj Pharmaceuticals Ltd. (India),
    • Pfizer Inc (The U.S),
    • Amgen Inc. (The U.S),
    • Avalon Pharma Private Limited (India),
    • Bachem Holding AG (Switzerland), and
    • Fujifilm Holdings Corporation (Japan).

    Market Dynamics

    An increasing number of people suffering from heart problems due to changing lifestyles and unhealthy eating habits is likely to drive the market growth significantly.

    The growth of the global glucagon market is primarily driven by the increasing prevalence of hypoglycaemia among people suffering from diabetes. Growing emphasis on the development of innovative products such as non-injectable emergency glucagon by the market players is the prominent trend noticed in the global glucagon market. Furthermore, the development of advanced drugs and therapies to treat hypoglycaemia is likely to create lucrative growth opportunities in the global glucagon market.

    Segment Analysis

    Application Trends

    Based on product type, the market has been segmented into injecting glucagon and nasal glucagon. The inject glucagon segment accounted for the largest market share in 2020 owing to widespread usage in the end-use applications.

    • Glucagon can be injected into the upper arm, stomach, or thigh.
    • The nasal glucagon segment is projected to register healthy CAGR during the review period on account of its increasing use in emergency cases.

    Regional Trends

    Geographically, the market in North America accounted for the largest market share in 2020 and is projected to continue its dominance during the review period.

    • The market growth can be attributed to the presence of an established healthcare industry and an increasing number of diabetic patients.
    • The market in Asia-Pacific is expected to increase at a healthy CAGR during the review period on account of rising product awareness and increased healthcare spending.

    COVID-19 Impact on Global Glucagon Market

    The covid-19 outbreak impacted the growth of the Glucagon market positively. People having diabetes were likely to face severe effects of the virus as compared to non-diabetic people. Thus, the demand for glucagon increased to maintain blood sugar levels. However, the supply of the product was affected for a short period amid lockdown as it resulted in restricted travel and supply chain disruptions.

    Critical Questions Answered in the Report

    • What are the key trends in the global glucagon market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the global glucagon market?
    • What are the key strategies adopted by the major vendors to lead in the global glucagon market?
    • What is the market share of the top vendors?

    To get a full scope of the report, click here…

    Target Audience

    Here is the list of the group of customers that the Global Glucagon market hopes to have the greatest opportunity to convert-

    • Glucagon manufacturers
    • Glucagon suppliers
    • Glucagon distributors
    • Organizations
    • Government bodies

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].

    Frequently Asked Questions (FAQs)

    The glucagon market is expected to witness an impressive growth of 6.1% CAGR in the coming years.

    Fresenius SE & Co. KGaA (Germany), Eli Lilly & Co. (The U.S), Novo Nordisk A/S (Denmark), Xeris Pharmaceuticals, Inc. (The U.S), Svar Life Science AB (Sweden), Taj Pharmaceuticals Ltd. (India), Pfizer Inc (The U.S), Amgen Inc. (The U.S), Avalon Pharma Private Limited (India), Bachem Holding AG (Switzerland) and Fujifilm Holdings Corporation (Japan) are among the key players in the glucagon market.

    The glucagon market is expected to reach USD 689.2 million in the foreseeable future.

    North America is expected to remain dominant in the glucagon market in the coming years.

    The inject glucagon segment accounted for the largest share of the glucagon market in 2020.

    Increasing prevalence of hypoglycaemia among people suffering from diabetes, growing emphasis on the development of innovative products such as non-injectable emergency glucagon, development of advanced drugs and therapies to treat hypoglycaemia are the factors driving the growth of glucagon market.

    Glucagon manufacturers, Glucagon suppliers, Glucagon distributors, Organizations, Government bodies are the target audience in the glucagon market.

    •